STATE-OF-THE-ART PAPER
The Pathogenesis of Myocardial Fibrosis in the Setting of Diabetic Cardiomyopathy
Juan Asbun, MD, PhD* and
Francisco J. Villarreal, MD, PhD ,*
* Escuela Superior de Medicina del Instituto Politécnico Nacional, Mexico City, Mexico
Department of Medicine, University of California, San Diego, California
Manuscript received May 19, 2005;
revised manuscript received August 24, 2005,
accepted September 26, 2005.
* Reprint requests and correspondence: Dr. Francisco J. Villarreal, UCSD, 9500 Gilman Drive, La Jolla, California 92093-0613J. (Email: fvillarr{at}ucsd.edu).
Diabetes has emerged as a major threat to worldwide health. The increasing incidence of diabetes in young individuals is particularly worrisome given that the disease is likely to evolve over a period of years. In 1972, the existence of a diabetic cardiomyopathy was proposed based on the experience with four adult diabetic patients who suffered from congestive heart failure in the absence of discernible coronary artery disease, valvular or congenital heart disease, hypertension, or alcoholism. The exact mechanisms underlying the disease are unknown; however, an important component of the pathological alterations observed in these hearts includes the accumulation of extracellular matrix (ECM) proteins, in particular collagens. The excess deposition of ECM in the heart mirrors what occurs in other organs such as the kidney and peritoneum of diabetics. Mechanisms responsible for these alterations may include the excess production, reduced degradation, and/or chemical modification of ECM proteins. These effects may be the result of direct or indirect actions of high glucose concentrations. This article reviews our state of knowledge on the effects that diabetes-like conditions exert on the cells responsible for ECM production as well as relevant experimental and clinical data.
This article has been cited by other articles:

|
 |

|
 |
 
F. G. Spinale, G. P. Escobar, R. Mukherjee, J. A. Zavadzkas, S. M. Saunders, L. B. Jeffords, A. M. Leone, C. Beck, S. Bouges, and R. E. Stroud
Cardiac-Restricted Overexpression of Membrane Type-1 Matrix Metalloproteinase in Mice: Effects on Myocardial Remodeling With Aging
Circ Heart Fail,
July 1, 2009;
2(4):
351 - 360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Messaoudi, P. Milliez, J.-L. Samuel, and C. Delcayre
Cardiac aldosterone overexpression prevents harmful effects of diabetes in the mouse heart by preserving capillary density
FASEB J,
July 1, 2009;
23(7):
2176 - 2185.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Matsushima, S. Kinugawa, T. Yokota, N. Inoue, Y. Ohta, S. Hamaguchi, and H. Tsutsui
Increased myocardial NAD(P)H oxidase-derived superoxide causes the exacerbation of postinfarct heart failure in type 2 diabetes
Am J Physiol Heart Circ Physiol,
July 1, 2009;
297(1):
H409 - H416.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Laczy, B. G. Hill, K. Wang, A. J. Paterson, C. R. White, D. Xing, Y.-F. Chen, V. Darley-Usmar, S. Oparil, and J. C. Chatham
Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system
Am J Physiol Heart Circ Physiol,
January 1, 2009;
296(1):
H13 - H28.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Caglayan, B. Stauber, A. R. Collins, C. J. Lyon, F. Yin, J. Liu, S. Rosenkranz, E. Erdmann, L. E. Peterson, R. S. Ross, et al.
Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator-Activated Receptor {gamma} in Cardiac Fibrosis
Diabetes,
September 1, 2008;
57(9):
2470 - 2479.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. S. Samuel, T. D. Hewitson, Y. Zhang, and D. J. Kelly
Relaxin Ameliorates Fibrosis in Experimental Diabetic Cardiomyopathy
Endocrinology,
July 1, 2008;
149(7):
3286 - 3293.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ueno, J. Suzuki, Y. Zenimaru, S. Takahashi, T. Koizumi, S. Noriki, O. Yamaguchi, K. Otsu, W.-J. Shen, F. B. Kraemer, et al.
Cardiac overexpression of hormone-sensitive lipase inhibits myocardial steatosis and fibrosis in streptozotocin diabetic mice
Am J Physiol Endocrinol Metab,
June 1, 2008;
294(6):
E1109 - E1118.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Venkatachalam, S. Mummidi, D. M. Cortez, S. D. Prabhu, A. J. Valente, and B. Chandrasekar
Resveratrol inhibits high glucose-induced PI3K/Akt/ERK-dependent interleukin-17 expression in primary mouse cardiac fibroblasts
Am J Physiol Heart Circ Physiol,
May 1, 2008;
294(5):
H2078 - H2087.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. P. Singh, K. M. Baker, and R. Kumar
Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production
Am J Physiol Heart Circ Physiol,
April 1, 2008;
294(4):
H1675 - H1684.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Fantoni, F. Regoli, A. Ghanem, S. Raffa, C. Klersy, A. Sorgente, F. Faletra, M. Baravelli, L. Inglese, J. A. Salerno-Uriarte, et al.
Long-term outcome in diabetic heart failure patients treated with cardiac resynchronization therapy
Eur J Heart Fail,
March 1, 2008;
10(3):
298 - 307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. M. Witteles and M. B. Fowler
Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
93 - 102.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Erdmann and R. G. Wilcox
Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure
Eur. Heart J.,
January 1, 2008;
29(1):
12 - 20.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Aragno, R. Mastrocola, G. Alloatti, I. Vercellinatto, P. Bardini, S. Geuna, M. G. Catalano, O. Danni, and G. Boccuzzi
Oxidative Stress Triggers Cardiac Fibrosis in the Heart of Diabetic Rats
Endocrinology,
January 1, 2008;
149(1):
380 - 388.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. van Heerebeek, N. Hamdani, M. L. Handoko, I. Falcao-Pires, R. J. Musters, K. Kupreishvili, A. J.J. Ijsselmuiden, C. G. Schalkwijk, J. G.F. Bronzwaer, M. Diamant, et al.
Diastolic Stiffness of the Failing Diabetic Heart: Importance of Fibrosis, Advanced Glycation End Products, and Myocyte Resting Tension
Circulation,
January 1, 2008;
117(1):
43 - 51.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Belmadani, J. Bernal, C.-C. Wei, M. A. Pallero, L. Dell'Italia, J. E. Murphy-Ullrich, and K. H. Berecek
A Thrombospondin-1 Antagonist of Transforming Growth Factor-{beta} Activation Blocks Cardiomyopathy in Rats with Diabetes and Elevated Angiotensin II
Am. J. Pathol.,
September 1, 2007;
171(3):
777 - 789.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. G. Frangogiannis, O. Dewald, Y. Xia, G. Ren, S. Haudek, T. Leucker, D. Kraemer, G. Taffet, B. J. Rollins, and M. L. Entman
Critical Role of Monocyte Chemoattractant Protein-1/CC Chemokine Ligand 2 in the Pathogenesis of Ischemic Cardiomyopathy
Circulation,
February 6, 2007;
115(5):
584 - 592.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Fulop, R. B. Marchase, and J. C. Chatham
Role of protein O-linked N-acetyl-glucosamine in mediating cell function and survival in the cardiovascular system
Cardiovasc Res,
January 15, 2007;
73(2):
288 - 297.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|